1.08
price up icon2.86%   0.03
after-market Handel nachbörslich: 1.07 -0.01 -0.93%
loading

An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten

pulisher
Jun 17, 2025

$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan

Jun 17, 2025
pulisher
Jun 13, 2025

Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace

Jun 13, 2025
pulisher
Jun 12, 2025

Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Pricing of Public Offering - PR Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - PR Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - Morningstar

Jun 11, 2025
pulisher
Jun 02, 2025

Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Allarity Therapeutics Announces First Patient Enrolled in - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - PR Newswire

Jun 02, 2025
pulisher
Jun 02, 2025

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 01, 2025

Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - The Malaysian Reserve

Jun 01, 2025
pulisher
May 31, 2025

Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for - GlobeNewswire

May 31, 2025
pulisher
May 31, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Yahoo Finance

May 31, 2025
pulisher
May 29, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

May 29, 2025
pulisher
May 28, 2025

Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS - PR Newswire

May 28, 2025
pulisher
May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - Business Wire

May 27, 2025
pulisher
May 27, 2025

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire

May 27, 2025
pulisher
May 23, 2025

Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail

May 23, 2025
pulisher
May 22, 2025

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - Yahoo Finance

May 22, 2025
pulisher
May 21, 2025

Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors - Yahoo Finance

May 21, 2025
pulisher
May 20, 2025

Viking Therapeutics: A High Potential Biotech Play With Manageable Risks (NASDAQ:VKTX) - Seeking Alpha

May 20, 2025
pulisher
May 19, 2025

Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st

May 19, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - Yahoo Finance

May 16, 2025
pulisher
May 14, 2025

Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data - Business Wire

May 14, 2025
pulisher
May 14, 2025

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire

May 13, 2025
pulisher
May 12, 2025

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire

May 12, 2025
pulisher
May 08, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider

May 08, 2025
pulisher
May 06, 2025

Aligos Therapeutics, Inc. SEC 10-Q Report - TradingView

May 06, 2025
pulisher
May 06, 2025

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire

May 06, 2025
pulisher
May 05, 2025

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics, Inc. Announces Results from the Phase 2 PIVOT-HD Study of PTC518 in Stage 2 and Stage 3 Huntington's Disease Patients - marketscreener.com

May 05, 2025
pulisher
May 01, 2025

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - The Victoria Advocate

May 01, 2025
pulisher
May 01, 2025

TransCode Therapeutics (RNAZ) Adjourns Special Meeting to May 2 - GuruFocus

May 01, 2025
pulisher
Apr 30, 2025

United Therapeutics Corporation Reports First Quarter 2025 Financial Results - Business Wire

Apr 30, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow

Apr 28, 2025
pulisher
Apr 28, 2025

Protara Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Apr 28, 2025
pulisher
Apr 26, 2025

Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC - Nasdaq

Apr 26, 2025
pulisher
Apr 25, 2025

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Business Wire

Apr 24, 2025
pulisher
Apr 23, 2025

Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) - GlobeNewswire

Apr 23, 2025
pulisher
Apr 21, 2025

TransCode Therapeutics Faces Crucial Reverse Split Decision as Special Meeting Falls Short of Quorum - Stock Titan

Apr 21, 2025
pulisher
Apr 21, 2025

Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com

Apr 21, 2025
pulisher
Apr 18, 2025

Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735 - Yahoo Finance

Apr 18, 2025
pulisher
Apr 14, 2025

Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire

Apr 14, 2025
pulisher
Apr 12, 2025

Why Summit Therapeutics Inc. (SMMT) Surged On Friday? - Insider Monkey

Apr 12, 2025
pulisher
Apr 11, 2025

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance - GlobeNewswire

Apr 11, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):